Search Results - Michel Delforge

Refine Results
  1. 1

    Multiple myeloma by Michel Delforge

    Published in HemaSphere (2018-06-01)
    Get full text
    Article


  2. 2

    Two Cases of Heavy Chain MGUS by Jan Van Keer, Björn Meijers, Michel Delforge, Gregor Verhoef, Koen Poesen

    Published in Case Reports in Oncological Medicine (2016-01-01)
    Get full text
    Article


  3. 3

    Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma by Jan Van Keer, Michel Delforge, Daan Dierickx, Kathelijne Peerlinck, Evelyne Lerut, Ben Sprangers

    Published in Case Reports in Hematology (2016-01-01)
    Get full text
    Article


  4. 4

    Genome-Wide CRISPR-Cas9 Knockout Screening Identifies <i>NUDCD2</i> Depletion as Sensitizer for Bortezomib, Carfilzomib and Ixazomib in Multiple Myeloma by Sophie Vlayen, Tim Dierckx, Marino Caruso, Swell Sieben, Kim De Keersmaecker, Dirk Daelemans, Michel Delforge

    Published in Hemato (2025-07-01)
    Get full text
    Article


  5. 5

    Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or... by Meletios A. Dimopoulos, Michel Delforge, Roman Hájek, Martin Kropff, Maria T. Petrucci, Philip Lewis, Annabel Nixon, Jingshan Zhang, Jay Mei, Antonio Palumbo

    Published in Haematologica (2013-05-01)
    Get full text
    Article


  6. 6

    Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review by Roman Hájek, Sebastian Gonzalez-McQuire, Zsolt Szabo, Michel Delforge, Lucy DeCosta, Marc S Raab, Walter Bouwmeester, Marco Campioni, Andrew Briggs

    Published in BMJ Open (2020-07-01)
    Get full text
    Article


  7. 7

    Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group by Frédéric Baron, Stefan Suciu, Sergio Amadori, Petra Muus, Heinz Zwierzina, Claudio Denzlinger, Michel Delforge, Antoine Thyss, Dominik Selleslag, Karel Indrak, Gert Ossenkoppele, Theo de Witte

    Published in Haematologica (2012-04-01)
    Get full text
    Article


  8. 8

    Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma by Isabel J.F. Hofman, Stephanie Patchett, Mark van Duin, Ellen Geerdens, Jelle Verbeeck, Lucienne Michaux, Michel Delforge, Pieter Sonneveld, Arlen W. Johnson, Kim De Keersmaecker

    Published in Haematologica (2017-08-01)
    Get full text
    Article


  9. 9

    Acquired von Willebrand syndrome secondary to monoclonal gammopathy: a single-center case series by Quentin Van Thillo, Finn Segers, Jan Brijs, Ulrike Douven, Radha Ramanan, Michel Delforge, Ann Janssens, Cédric Hermans, Johan De Bent, Marc Jacquemin, Thomas Vanassche, Peter Verhamme

    Published in Therapeutic Advances in Hematology (2025-06-01)
    Get full text
    Article


  10. 10

    Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes by Jasper Edgar Neggers, Bert Kwanten, Tim Dierckx, Hiroki Noguchi, Arnout Voet, Lotte Bral, Kristien Minner, Bob Massant, Nicolas Kint, Michel Delforge, Thomas Vercruysse, Erkan Baloglu, William Senapedis, Maarten Jacquemyn, Dirk Daelemans

    Published in Nature Communications (2018-02-01)
    Get full text
    Article


  11. 11

    Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study by Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel

    Published in HemaSphere (2023-09-01)
    Get full text
    Article


  12. 12

    Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma by Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

    Published in Haematologica (2024-02-01)
    Get full text
    Article


  13. 13

    Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network by Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel, Hermann Einsele

    Published in Haematologica (2019-12-01)
    Get full text
    Article


  14. 14

    Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice by Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Sophie Vandervennet, Sandra Van Hoorenbeeck, Evelien Moorkens, Danielle Strens, Joris Diels, Francesca Ghilotti, Benjamin Haefliger, Sander Dalhuisen, William Deraedt, Sébastien Anguille

    Published in HemaSphere (2022-12-01)
    Get full text
    Article


  15. 15

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma by Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen Miller, Eunpi Cho, Fredrik Schjesvold

    Published in Clinical Hematology International (2023-01-01)
    Get full text
    Article


  16. 16

    P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL)... by Michel Delforge, Krina Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas Marshall, Bertrand Arnulf, Michele Cavo, Ajay Nooka, Salomon Manier, Natalie Callander, Sergio Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa Mckiver, Mark Cook, Paula Rodríguez-Otero

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  17. 17

    Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States by Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge, Nirali Kotowsky, Jacopo Bitetti, Natalie Boytsov, Leena Camadoo-O'Byrne, Lindsey Powers Happ, Guillaume Germain, Ana Urosevic, Malena Mahendran, Mei Sheng Duh, Francois Laliberte, Michele Cavo, Hans C. Lee

    Published in Haematologica (2024-10-01)
    Get full text
    Article


  18. 18

    PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE by Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Michel Delforge, Nirali Kotowsky, Jacopo Bitetti, Natalie Boytsov, Leena Camadoo-O’byrne, Lindsey Powers Happ, Mujib Rohman, Guillaume Germain, Mei Sheng Duh, François Laliberté, Malena Mahendran, Ana Urosevic, Hans C. Lee

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  19. 19

    Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a... by Theo de Witte, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen, Eva Hellström-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze

    Published in Haematologica (2010-10-01)
    Get full text
    Article


  20. 20

    Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up by Meletios A. Dimopoulos, Philippe Moreau, Evangelos Terpos, María-Victoria Mateos, Sonja Zweegman, Gordon Cook, Michel Delforge, Roman Hájek, Fredrik Schjesvold, Michele Cavo, Hartmut Goldschmidt, Thierry Facon, Hermann Einsele, Mario Boccadoro, Jesús San-Miguel, Pieter Sonneveld, Ulrich Mey, on behalf of the EHA Guidelines Committee and the ESMO Guidelines Committee

    Published in HemaSphere (2021-02-01)
    Get full text
    Article


Search Tools: